Editas Medicine (EDIT) Q4 2025 earnings summary

Executive summary

• Lead candidate EDIT-401 showed over 90% mean LDL-C reduction in preclinical studies and is on track for IND/CTA submission by mid-2026.

• First-in-human clinical trial in HeFH patients planned for late 2026, with early proof-of-concept data expected by year-end 2026.

• Strong cash position with runway into Q3 2027 supports ongoing development milestones.

Financial highlights

• Cash and cash equivalents were $146.6M as of December 31, 2025, down from $269.9M at year-end 2024.

• Q4 2025 net loss was $5.6M ($0.06/share), a significant improvement from $45.4M ($0.55/share) in Q4 2024.

• Full year 2025 net loss was $160.1M ($1.80/share), improved from $237.1M ($2.88/share) in 2024.

• Q4 2025 revenues were $24.7M, down from $30.6M in Q4 2024; full year 2025 revenues were $40.5M, up from $32.3M in 2024.

• Research and development expenses for 2025 decreased to $90.0M from $199.2M in 2024.

Outlook and guidance

• IND/CTA submission for EDIT-401 expected by mid-2026.

• First-in-human trial for HeFH patients to begin in 2026, with topline data anticipated in 2027.

• Cash runway projected into Q3 2027, supporting planned milestones.